Cargando…
Updates on the Treatment of Essential Hypertension: A Summary of AHRQ’s Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Direct Renin Inhibitors
Autores principales: | Powers, Benjamin, Greene, Laurence, Balfe, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437760/ https://www.ncbi.nlm.nih.gov/pubmed/22088101 http://dx.doi.org/10.18553/jmcp.2011.17.s8.1 |
Ejemplares similares
-
Summary of AHRQ's Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
por: White, Michael, et al.
Publicado: (2011) -
Summary of AHRQ’s Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis
por: McMahan, Robert, et al.
Publicado: (2012) -
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update
por: Shukla, Ashwin Kumar, et al.
Publicado: (2021) -
Commentary to Angiotensin-Converting-Enzyme 2 and Renin–Angiotensin System Inhibitors in COVID-19: An Update
por: Ferri, Claudio, et al.
Publicado: (2021) -
Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)